The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates of 27.1% and 17.6% ...

41,366 people played the daily Crossword recently. Can you solve it faster than others?41,366 people played the daily Crossword recently. Can you solve it faster than others?

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

LUBBOCK, Texas (KCBD) - The nasal spray Spravato, also known as esketamine ... but this approval is a step in the right direction. “I cannot guarantee that this medication will work on a ...

Call our team to schedule a 1-hour virtual intake assessment to see if you can benefit from treatment by Stella Mental Health. Intake assessments, Spravato, TMS therapy, integration therapy and ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...

As a leading ketamine clinic and Spravato treatment center ... Your journey to healing begins with a simple step. Schedule a free, 20-minute, confidential 1-on-1 call with our compassionate ...